IP Library › Granted Patent US 11,453,870
Granted Patent B2
US 11,453,870 · App. 17/374,262 · Granted Sep 27, 2022

Ligase fusion proteins and application thereof

Inventors: Gang Qin (Suzhou, CN); Cao Lv (Suzhou, CN); Joachim Walter (Mittelbiberach, DE); Rolf Werner (Biberach an der Riss, DE); Yunpeng Zhong (Suzhou, CN)
Assignee: GENEQUANTUM HEALTHCARE (SUZHOU) CO. LTD.
C12N9/52A61K47/6801C12N11/06C12Y304/2207C07K2319/61
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,453,870
App. No.
17/374,262
Granted
Sep 27, 2022
Kind
B2
Abstract

The present disclosure relates to the field of biotechnology. In particular, provided are a ligase fusion protein and an immobilized ligase comprising the same. Also provided is use of the ligase fusion protein or the immobilized ligase in the preparation of conjugates. Further provided is a process for the preparation of conjugates using a ligase or a ligase unit.

Claims (5)

1. A ligase fusion protein consisting of a ligase, a Halo tag, and optionally a linker peptide, wherein the ligase, the Halo tag, and optionally the linker peptide are fused by a covalent bond, wherein the ligase is a sortase A comprising the amino acid sequence of SEQ ID NO:27 or an amino acid sequence having a sequence identity of at least 85% thereto, and wherein the ligase has an isoelectric point (pI) of about 7.5 to about 10.0, the Halo tag has an isoelectric point of about 4.5 to about 5.0, and the pI of the ligase fusion protein is about 2.0 to about 4.5 pH units lower than that of the ligase.

2. The ligase fusion protein according to claim 1 , wherein the Halo tag comprises the amino acid sequence of SEQ ID NO: 28 or an amino acid sequence having a sequence identity of at least about 85% thereto.

3. The ligase fusion protein according to claim 1 , wherein the pI of the ligase fusion protein is about 4.5 to about 6.5.

4. The ligase fusion protein according to claim 1 , wherein the pI of the ligase fusion protein is about 5.0 to about 6.0.

5. The ligase fusion protein according to claim 1 , wherein the ligase fusion protein has the amino acid sequence of SEQ ID NO: 29.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT APPLICATION NUMBER 17/364,262 WHICH SHOULD HAVE BEEN ENTERED AS 17/374,262 PREVIOUSLY RECORDED AT REEL: 057909 FRAME: 0150. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 30, 2022
From: QIN, GANG; LV, CAO; WALTER, JOACHIM; WERNER, ROLF; ZHONG, YUNPENG
To: GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
Reel/Frame 061619/0307 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE APPLICATION NUMBER PREVIOUSLY RECORDED AT REEL: 057909 FRAME: 0150. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 9, 2022
From: QIN, GANG; LV, CAO; WALTER, JOACHIM; WERNER, ROLF; ZHONG, YUNPENG
To: GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
Reel/Frame 061119/0307 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2021
From: QIN, GANG; LV, CAO; WALTER, JOACHIM; WERNER, ROLF; ZHONG, YUNPENG
To: GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
Reel/Frame 057909/0150 →
Priority Claims (1)
WO PCT/CN2021/074082 · Jan 28, 2021 · international
Continuity (1)
Related Publication 20220251530A1 · Aug 11, 2022
Cited By (2)
US 12,467,103 US 12,539,336